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ABSTRACT
Background Technological advances and high throughput 
biological assays can facilitate discovery science in 
biobanks from population cohorts, including pregnant 
women. Biological pathways associated with health 
outcomes differ depending on geography, and high- income 
country data may not generalise to low- resource settings. 
We conducted a systematic review to identify prospective 
pregnancy cohorts in sub- Saharan Africa (SSA) that include 
biobanked samples with potential to enhance discovery 
science opportunity.
Methods Inclusion criteria were prospective data 
collection during pregnancy, with associated biobanking 
in SSA. Data sources included: scientific databases 
(with comprehensive search terms), grey literature, 
hand searching applicable reference lists and expert 
input. Results were screened in a three- stage process 
based on title, abstract and full text by two independent 
reviewers. The review is registered on PROSPERO 
(CRD42019147483).
Results Fourteen SSA studies met the inclusion criteria 
from database searches (n=8), reference list searches 
(n=2) and expert input (n=4). Three studies have ongoing 
data collection. The most represented countries were 
South Africa and Mozambique (Southern Africa) (n=3), 
Benin (Western Africa) (n=4) and Tanzania (Eastern Africa) 
(n=4); including an estimated 31 763 women. Samples 
commonly collected were blood, cord blood and placenta. 
Seven studies collected neonatal samples. Common 
clinical outcomes included maternal and perinatal 
mortality, malaria and preterm birth.
Conclusions Increasingly numerous pregnancy cohorts 
in SSA that include biobanking are generating a uniquely 
valuable resource for collaborative discovery science, 
and improved understanding of the high regional risks of 
maternal, fetal and neonatal morbidity and mortality. Future 
studies should align protocols and consider their added 
value and distinct contributions.
INTRODUCTION
Recently, the proliferation of fast throughput 
biological assays and ‘omics technologies 
(genomics, epigenomics, metabolomics, lipi-
domics and proteomics), as applied to large 
biorepositories, has enabled discovery science 
at scale.1 Studies that include biorepositories 
facilitate the study of relationships between 
clinical and environmental data, outcomes 
and multilayered biological variables—at 
both individual and population levels.2 This 
approach has the capacity to provide a holistic 
Key questions
What is already known?
 ► Availability of large- scale biorepositories and ad-
vances in ‘omics technology have opened up the 
possibility of discovery science to better understand 
adverse maternal and neonatal outcomes.
 ► Sub- Saharan Africa has the highest burden of such 
outcomes globally, and the creation of biobanks is a 
rapidly increasing field of research to support inter-
ventions to reduce these outcomes.
What are the new findings?
 ► This is the first systematic review to specifically fo-
cus and characterise all sub- Saharan African preg-
nancy cohorts that include biological samples stored 
for future research.
 ► The majority of these cohorts have been established 
within the last decade and together provide a rich set 
of biological samples such as blood, cord blood and 
placenta, to aid global health researchers in better 
understanding disease pathways in African women.
 ► Most of these cohorts include women who are at-
tending facilities, and do not provide long- term 
maternal- infant follow- up.
What do the new findings imply?
 ► Given the time, resources and efforts required—by 
both researchers and participants—to contribute, 
collect and store biological samples, future projects 
in sub- Saharan Africa planning to establish biobanks 
can offer value through complementing existing 
cohorts.
 ► Further, this field would benefit from continued stan-
dardisation of protocols for biobanking to enable 
data sharing and collaboration, and careful consid-
eration of global health research priorities.
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picture of health and shed light on the biological mecha-
nisms underlying both health and disease.3
This approach is essential in maternal and perinatal 
research as the relationships between adverse preg-
nancy/birth outcomes, environmental exposures (eg, 
climate, nutrition, infection) and genome and pheno-
typic characteristics are only beginning to be under-
stood.4 Researchers in higher resourced settings such as 
the United Kingdom, the Netherlands and Scandinavia 
have established large pregnancy cohorts and biobanks 
to help address these questions.5–8 However, there are 
challenges in applying the results from these and other 
high- income country studies, to low and middle- income 
countries, where the biological mechanisms, risk factors, 
environmental exposures and clinical outcomes may 
differ.9 10
Sub- Saharan Africa (SSA) has the highest burden of 
maternal, perinatal and child deaths globally,11 12 yet little 
is known about the complex interactions between context- 
specific exposures and the biological mechanisms that 
inevitably underlie this excess in deaths.9 10 Better under-
standing of these processes would guide prevention, 
screening and treatment measures, and has the potential 
to inform resource allocation and distribution, as well as 
health policy at regional and country levels.
To determine the extent of biobanking and discovery 
science in SSA, current gaps and areas the global health 
community should prioritise, we conducted a system-
atic review of pregnancy cohorts that include biological 
samples stored in biorepositories for future research 
use. In light of the recent shift in focus of global health 
research to centre around the COVID-19 pandemic, such 
studies are particularly pertinent as they will provide valu-
able resources to generate important knowledge.
METHODS
This review has been developed in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) checklist13 and is registered on 
PROSPERO (CRD42019147483). The PRISMA checklist 
is included as Online Supplemental File 1.
Objective
Our objective was to systematically review pregnancy 
cohort studies that include biobanking in SSA. For our 
purposes outlined here, biobanking was broadly defined 
to include any biological sample collected and stored 
for future use—excluding samples collected solely for 
point- of- care testing. Additionally, the review aimed to 
characterise the study designs of the cohorts, their popu-
lations, exposures and outcomes reported, as well as to 
examine the completeness of participant follow- up. By 
determining the number and depth of existing biobanks, 
this review provides a resource for addressing current 
knowledge gaps. Identifying these gaps is pivotal in 
order to generate new evidence for improving maternal 
and newborn health in the region—and for framing 
recommendations for future cohort study- based research 
and biobanks.
Study inclusion and exclusion
All prospective studies of pregnant women in SSA 
conducted between 1 January 2000 and 30 September 
2019 that collected clinical, and if relevant, sociological 
data, and have biobanked samples for future use were 
eligible for inclusion. While we expected most cohorts 
to be recent due to technological development in metab-
olomics and research inclusive of deep phenotyping, we 
extended our search back to 2000 to ensure no earlier 
cohorts were missed. Studies were assessed by reviewing 
study sampling methods, laboratory protocols or standard 
operating procedures (SOPs) for explicit indication that 
samples were collected and stored for future use, or for 
subsequent immediate analysis. In cases (two) where this 
was unclear, we approached the study authors for clar-
ification on sample storage indication and purpose of 
sample use. Both randomised and observational studies 
were included. Randomised trials were included as often 
the data sets/samples would be available as a ‘cohort’ 
for secondary analyses. Exclusion criteria consisted of 
cohorts collecting biological samples exclusively from 
non- pregnant women, studies outside SSA, studies 
collecting samples for point- of- care assays only and 
studies conducted prior to the year 2000. In the case of 
multiple articles referencing the same study/cohort, only 
one report with the most comprehensive information was 
included, but data from multiple publications may have 
been collated (ie, from both the protocol and subsequent 
publications).
Search strategy
The primary search was conducted in MEDLINE, Embase, 
Web of Science, Africa Index Medicus and CAB Direct. 
A combination of Medical Subject Headings (MeSH) 
terms related to geographical location (SSA), pregnancy 
and pregnancy- related adverse outcomes and biological 
samples was used. Search terms are included in Online 
Supplemental Table S2. All searches were conducted 
from July through September 2019, with the search date 
cut- off excluding studies published after 30 September 
2019.
Results were screened in a three- stage process based on 
title, abstract and then full- text review. At each stage, all 
titles, abstracts and full papers were reviewed by two inde-
pendent reviewers (JB, KP), and in the case of disagree-
ment, a third reviewer (MLWK) assisted to break the 
tie. Duplicates were excluded using R statistical software 
V.3.5.3.14 Additional articles were identified through 
hand searching the references of included papers, and 
input from experts in the field.
Data extraction
Data were extracted independently by the two reviewers 
and recorded using an Excel spreadsheet. In the case of 
disagreements these were resolved via discussion, and if 
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necessary, the intervention of the third reviewer (MLWK). 
The data extracted from each included study comprised 
year(s) of publication and active data collection, geog-
raphy and study design, samples collected, and maternal 
and perinatal mortality and morbidities.
Data analysis
Data regarding the volume collected, storage method 
and timing of each biological sample were summarised. 
For each biological sample, the proportion of studies 
collecting this sample was reported. Storage and gesta-
tional timing of collection information was similarly 
summarised. If any biological sample was collected (with 
collection data) in at least two studies, then the rates 
of ascertainment (total participants with sample/total 
participants in study) were combined with mixed effects 
logistic regression, treating the study as a random effect. 
In these cases, the overall rate and 95% confidence inter-
vals (CIs) were reported, together with I² statistics, for 
heterogeneity. Clinical outcomes with rates reported in at 
least two studies were also combined. All statistical anal-
yses were conducted using R version V.3.5.3.14
Quality and risk of bias assessment
Each included study was assessed for quality using the 
Newcastle- Ottawa Scale for cohort studies (http://www. 
ohri. ca/ programs/ clinical_ epidemiology/ oxford. asp) 
according to selection of the study group (score 0–4), 
comparability of the groups (score 0–2) and ascertain-
ment of outcomes (score 0–3). Complete details are given 
in Online Supplemental Table S3. A PRISMA checklist13 
for this review is included (Online Supplemental File 1).
Patient and public involvement
Patient/public involvement was unfortunately not 
feasible in this review.
RESULTS
In total, 14 cohorts were identified that met the inclu-
sion criteria.9 10 15–27 Eight of these were identified from 
the search terms and strategy outlined above, two from 
hand searching references of identified articles and two 
via expert input. For one of the four studies identified 
through expert input,17 the protocol is pending publica-
tion. See figure 1 for details.
 
Papers identified through database 
searches 
(n = 2306)
Papers identified through expert 
input, and other sources
(n = 17)
Total number of papers after duplicates removed
(n = 2094)
Number of titles screened 
against eligibility criteria
(n = 2094)
Titles excluded
(n = 2043)
Number of full-text papers 
reviewed
(n = 51)
Full-text papers excluded 
(with rationale for 
exclusion)
Final papers included in 
analysis
(n = 14)
Figure 1 Study eligibility and inclusion flow chart.
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Studies were spread across eight countries, with 
Tanzania and Benin each being the most common loca-
tion (with four studies in each country). Five studies were 
multicountry (within SSA), four of these9 15 19 22 being 
the three largest included (n=2032, 4732, 4749 and 11 
800, respectively). There were also two studies10 27 that 
included both sites inside and outside SSA, mainly in 
South Asia. Nine had completed data collection and 
published details, with a median sample size of 953 
(IQR=472–2707); the smallest had 250 participants.24 The 
Bill & Melinda Gates Foundation was the most common 
funder, with three studies acknowledging this organi-
sation as the sole or partial funder. Otherwise, funding 
sources were predominately from either European coun-
tries or the European Union, with the smallest cohort24 
funded by the South African Medical Research Council. 
All but one16 protocol/study were published within the 
past 10 years, with five studies published in 2019, and one 
in 2020. Cohorts were broadly similar in terms of their 
inclusion criteria and target populations. Full details of 
each included publication are shown in table 1.
All protocols, except for the Functional Classification of 
Abnormal Fetal and Neonatal Growth Phenotypes, Newborn 
Case Control Study (INTERBIO- 21st), had multiple sampling 
points, and all but the Seychelles Child Development Study 
collected samples at delivery. Nine included postpartum 
sampling.9 10 15–18 24–26 The samples most commonly collected 
were maternal blood (14 studies) and placenta (11 studies). 
Where reported, ascertainment rates of sample collection 
from participants were high; for example, the pooled rate 
of women providing at least one blood sample was 92.0% 
(95% CI 83.1% to 96.4%). Hair, vaginal swabs, tissue and 
breast milk were less frequently collected (≤2 studies in 
all cases). Eight studies reported collection of neonatal 
samples,9 10 15–18 21 26 and of these, cord blood and neonatal 
blood were most common. Table 2 provides details of sample 
collection.
The gestational time of sampling varied across 
cohorts, and also differed by sample type. As illustrated 
in table 3, blood sample collection occurred primarily in 
the antenatal period, with 9, 10 and 11 studies collecting 
samples in the first, second and third trimesters, respec-
tively. Nine studies collected blood at delivery and 
six collected blood post partum (see table 3); many 
also collected cord blood and/or placenta samples at 
delivery (see table 2).
Most studies recorded all the principal clinical 
outcomes outlined for data extraction, with maternal 
mortality, anaemia, stillbirth and neonatal death being 
the most common. Despite this, as many are either 
ongoing, or have yet to publish primary results, few have 
reported outcome data on those outcomes we described 
a priori. Where data were available, we pooled outcome 
rates and found a maternal mortality ratio of 120 (95% 
CI 80 to 280; 24 women, 8 studies, I2=14.6%) per 100 000 
births, and stillbirth and neonatal death rates of 20 (95% 
CI 15 to 28; 297 fetuses, 7 studies, I2=84.6%) and 11 (95% 
CI 6 to 20; 154 infants, 5 studies, I2=89.1%) per 1000 total 
and live births, respectively. Pregnancy hypertension, 
maternal anaemia and malaria had rates of 3.4% (95% CI 
2.6% to 4.4%, 59 women, 2 studies, I2=NA), 37.4% (95% 
CI 22.0% to 55.9%, 4868 women, 8 studies, I2=99.1%) 
and 5.2% (95% CI 0.90% to 24.4%, 440 women, 4 studies, 
I2=99.5%), respectively. Full details of clinical outcomes 
are provided in table 4. Additional outcomes collected in 
at least two studies—but not presented here—were HIV 
and diabetes (two studies each), and low birth weight 
(four studies). Only three studies had long- term (greater 
than one year) maternal or paediatric outcomes.
DISCUSSION
Summary of findings
All fields of clinical research increasingly acknowledge 
the importance of pathways that can only be studied 
with biological analyses, including modern ‘omics tech-
niques, such as genomics, transcriptomics and metabolo-
mics—with epigenomics becoming increasingly popular. 
Maternal health and pregnancy studies are no exception, 
with many studies beginning to assess the significance of 
these relationships.5–8 Until recently, the collection of 
such samples and in- depth biological investigation have 
taken place almost exclusively in high- income settings 
and populations.
This systematic review set out to determine to what 
extent biobanking has been implemented in pregnancy 
studies in SSA. In many lower resourced settings in SSA, 
women face distinct challenges and a higher burden of 
morbidity and mortality than those in higher resourced 
settings.11 12 The findings of this review suggest that 
biological sampling is gaining popularity in SSA, as all 
the included cohorts either completed data collec-
tion within the past decade, or have data collection 
ongoing. The included studies can be broadly grouped 
into two categories: clinical studies or trials that include 
biological sampling, or those with a primary focus on 
biobanking and discovery science. For example, both the 
Community- based Scheduled Screening and Treatment 
of Malaria in Pregnancy for Improved Maternal and 
Infant Health Consortium (COSMIC), and Strategies 
TO Prevent Pregnancy- Associated Malaria (STOPPAM) 
studies reported malaria as the primary outcome, but 
undertook biological sampling for malaria testing, prev-
alence and treatment effects.19 22 Many similar malaria 
studies were excluded as blood samples were not banked 
for future research (or not indicated for this purpose). 
This was also true of many HIV and anaemia- focused 
cohorts, where sampling was for point- of- care testing or 
immediate biomarker assessment only.
This review has also revealed that for the most part, 
SSA- based biobanking pregnancy studies do not operate 
in isolation and are often part of larger global consortia 
(INTERBIO- 21st, Alliance for Maternal and Newborn 
Health Improvement (AMANHI), Zambian Preterm Birth 
Prevention Study/Global Alliance to Prevent Prematurity 
and Stillbirth (ZAPPS/GAPPS), Healthy Life Trajectories 
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Initiative (HeLTI), Pregnancy Care Integrating Trans-
lational Science, Everywhere (PRECISE)9 10 17 21 27). 
INTERBIO- 21st and AMANHI, for example, are compre-
hensive in scope, collecting data on a wide variety of 
clinical outcomes and addressing possible associations 
with biomarkers.10 27 These cohorts both contribute to 
larger global consortia—including partnerships with 
South Asia—as well as Brazil and the UK, in the case of 
INTERBIO- 21st.27 To date, ‘at scale’ biomarker or ‘omics 
data are unavailable for either of these cohorts, but 
forthcoming ‘between- country’ comparisons of disease 
pathways are likely to offer the optimal understanding 
of regional variability in disease aetiology. Further, the 
above- mentioned biobanks9 10 17 21 27 are harmonised 
in terms of informed consent (using a tiered informed 
consent model), and collection, processing and storage 
SOPs, which will enable future pooling of samples 
(currently being funded through the Missed Oppor-
tunities in Maternal and Infant Health consortium).9 
This harmonisation across operations can provide more 
ample opportunity for future collaboration, increases the 
likelihood that banked samples will be used—as well as 
increases the comparability of findings across studies.
The most commonly collected samples in the included 
studies were maternal venous blood, cord blood and 
urine. These are all simple to collect and have high 
Table 2 Biobanking information (sample type proportions, and timing)
Sample
Number of studies 
collecting
Collected 
antepartum
Collected at 
delivery
Collected 
postpartum
Reporting 
number of 
subjects with 
sample*
Proportion of subjects 
with at least one 
sample collected 
(weighted)† I2
Blood 14 (100%)9 10 15–19 22–24 26 27 13 (92.9%) 9 (64.3%) 8 (57.1%) 7 (50.0%) 92.0% (83.1%, 96.4%) 99.6%
Vaginal swab 2 (14.2%)9 26 2 (14.2%) 2 (14.2%) 0 (0.0%) 0 (0.0%) – –
Hair 1 (7.1%)23 1 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) – –
Cord blood 11 (78.6%)9 10 15 16 18–22 24 – 11 (78.60%) NA 4 (36.4%) 70.3% (47.5%, 86.0%) 99.6%
Urine 7 (50.0%)9 10 15 16 18 22 26 7 (50.0%) 6 (42.9%) 6 (42.9%) 0 (0.0%) – –
Stool 3 (21.4%)10 15 19 2 (14.2%) 3 (21.4%) 1 (7.1%) 0 (0.0%) – –
Placenta 11 (78.6%)9 10 15 17–21 24 26 27 – 11 (78.6%) NA 5 (45.4%) 68.0% (49.0%, 82.4%) 99.7%
Tissue 2 (16.6%)10 26 2 (14.2%) 2 (14.2%) 1 (7.1%) 0 (0.0%) – –
Breast milk 3 (25.0%)16 18 22 – – 3 (25.0%) 0 (0.0%) – –
Neonatal urine 0 (0.0%) – – 0 (0.0%) 0 (0.0%) – –
Neonatal stool 2 (16.6%)9 10 – – 2 (16.6%) 0 (0.0%) – –
Neonatal blood 6 (42.9%)9 18 20–22 26 – – 6 (42.9%) 1 (16.6%) – –
*Denominatoris number on studies collecting corresponding sample.
†Based onrandom effects logistic regression model.
Table 3 Timing of maternal blood samples across studies
Study
Pre- 
pregnancy
First 
trimester
Second 
trimester
Third 
trimester Delivery
48 hours 
postpartum
6 weeks 
postpartum
6 months 
postpartum
12 months 
postpartum
60 months 
postpartum
IPTp +21 X X X X X
STOPPAM24 X X X X
Seychelles Child 
Development 
Study23
X
MiPADD20 X X X X X
ENID18 X X
COSMIC27 X X X
FOETAL17 X X X
RECIPAL15 X X X
AMANHI10 X X X X X
INTERBIO- 21st19 X
NuPED16 X X X X X X
ZAPPS26 X X X X
PRECISE9 X X X X X X
HeLTI22 X X X X X
X indicates data is collected at that time point.
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analytical utility. Blood was collected in 92.0% of women 
from the five studies reporting. It is encouraging that 
placenta samples were taken in 11 of the 14 studies as 
these are a valuable resource for future analyses. In the 
studies with publicly available data, both cord blood and 
placenta samples were ascertained in ~70% of subjects. 
This represents a further success, given the challenges 
associated with following women to delivery, collecting 
at time- of- delivery samples and transporting samples 
to the laboratory in time for adequate processing and 
biobanking.28
Most cohorts captured standard maternal and peri-
natal outcomes. Preterm birth (based on estimated 
gestation at birth) was a common primary or secondary 
outcome, having a high incidence and reported associa-
tions with several biomarkers (eg, alpha- fetoprotein and 
C- reactive protein).29 Maternal mortality was another, 
with the pooled maternal mortality ratio from six studies 
being 150 per 100 000 (95% CI 80 to 280), however lower 
than previously reported rates for SSA as a whole.30 Simi-
larly, pooled stillbirth and neonatal death rates were 
lower than those reported for the region. This may indi-
cate selection bias in the participant populations, lack 
of follow- up to 42 days post partum or perhaps a conse-
quence of engagement in research, where more compre-
hensive obstetric care may be available.
Biobanking in context
The unique challenges faced by health systems in SSA 
highlight the potential for biobanking studies on the 
continent to address gaps in public and global health 
domains. Further, African- based and African- led biore-
positories offer opportunities for training, capacity 
building and contributions to health and scientific infra-
structure. However, the establishment of biobanking 
studies is not without its own set of challenges. This can 
involve complex processes for governance and culturally 
appropriate data and sample collection. The movement 
(particularly across borders) and storage of data and 
samples can be both ethically and logistically complex. 
Resource and supply- heavy operating procedures, as 
well as funding longevity, pose additional challenges.31 32 
Robust partnerships and collaborations between proposed 
and existing biobanking initiatives may offer innovative 
strategies for expanding research and research capaci-
ties, while minimising the above- mentioned challenges. 
However, inadequate biobanking regulatory frameworks 
and insufficient global governance structures continue to 
be issues of debate.31 32 Furthermore, in some countries 
anxiety around use of samples for future research has led 
to regulatory barriers with, in some cases, limits being 
imposed on the number of years samples can be stored.33 
As such, it is essential that future biobanking initiatives 
and partnerships be aware of these potential pitfalls, and 
equitably benefit all parties involved.
The new focus on investigation in SSA and other lower 
and middle- income countries clearly parallels the burden 
of disease. While pregnancy cohorts for discovery science 
have previously been concentrated on populations in the 
global North, the shift to the global South is appropriate 
due to the recognition that differing biological ‘routes’ 
may lead to the same adverse outcome, depending on 
geographical setting.34 Examples include the Prema-
turity Reduction by Pre- eclampsia Care study in Brazil 
which will use biomarkers to assess risk factors for pre- 
eclampsia in women across six Brazilian cities.34 Similarly, 
in India—and using an integrated approach (clinical, 
epigenetics, epigenomics, genomics, proteomics and 
microbial)—the Interdisciplinary Group for Advanced 
Research on Birth Outcomes- DBT India Initiative has 
followed >4000 women throughout their pregnancies to 
determine potential predictors for preterm birth.30 The 
PRECISE Network in West (The Gambia), East (Kenya) 
and Southern (Mozambique) SSA9 35 36 was established 
to understand the social, clinical and biological determi-
nants of healthy and complicated pregnancy outcomes. 
These studies highlight the potential for pregnancy 
cohorts and high throughput technologies to improve 
the understanding of common pregnancy complications 
in the locations where they occur, offering the greatest 
opportunity for appropriately targeted interventions.
Finally, given the increased emphasis and shifting 
focus of global health research to the novel COVID-19 
pandemic, biobanks have the potential to be an important 
and unique resource for furthering our understanding of 
the risks and implications of this disease in pregnancy.
Strengths
To our knowledge, this is the first systematic review to 
assess the scope of biobanking studies in prospective 
pregnancy cohorts in SSA, and to report on the diversity 
of samples collected. While a previous review published 
in 2011 included both retrospective and prospective 
studies, this review reported only on blood sampling, and 
reported high attrition rates in cohorts, while also high-
lighting the absence of large- scale cohorts.37 Our review, 
comprehensive in inclusion of scientific databases, 
sampling protocols and secondary sources, illustrates a 
rapidly evolving landscape over the intervening years.
Limitations
The most significant challenge encountered was the 
infrequent use of the term ‘biobanking’. While collection 
and storage of biological samples for future purposes is 
common, few studies explicitly referred to this process as 
‘biobanking’. Extension of our definition of biobanking 
to include studies mentioning collection and storing of 
samples for future use, ancillary purposes or substudies 
may have led to exclusion of those with no explicit 
mention of sample storage. The database search also 
presented challenges, as the MeSH terms and keywords 
often did not accurately reflect the specific study infor-
mation. Based on discussion with members of the global 
health community, there may be additional studies or 
internal quality improvement projects taking place in 
SSA that have not yet reported their biobanks. Also, some 
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studies ineligible for inclusion are newly established, 
and consequently, their protocols are not yet published. 
Therefore, the total number included may have been 
underestimated. Notwithstanding this, our comprehen-
sive search was unlikely to have missed well- established 
cohorts.
Recommendations for future research
The cohorts identified provide a full picture of the state 
of biobanking in maternal health research in SSA and 
offer clear indications to where gaps exist, and where 
they are being addressed. In particular, we found 
very few studies with detailed long- term follow- up of 
mother–infant pairs or studies which include compre-
hensive neonatal samples. Only one study included 
pre- pregnancy data, and with an increasing global focus 
on preconception health this focus is likely to become 
more common.33 Given that few studies have been, 
or are, collecting hair, stool, vaginal swabs, tissue and 
breast milk samples, the biological data and research 
findings that can be obtained from these sample types 
should not be considered a representative overview 
for SSA. Depending on feasibility and the objectives of 
future studies, collection of these sample types may be 
warranted for inclusion. Finally, as the majority of SSA 
countries are not included in these studies, and given 
the relatively lower maternal and perinatal mortality 
rates compared with regional estimates,11 12 it is possible 
that populations of SSA women who are at higher risk 
are under- represented. Also, the majority of these 
studies include women who deliver in health facilities, 
and consequently miss many women who are unable to 
deliver in these facilities (eg, those women from rural or 
remote locations or without access to transport). Future 
studies which include these most vulnerable popula-
tions of women constitute a priority.
Further, publications by existing cohort studies will 
be useful in identifying those available for future use. 
Publicly available protocols accessible early in a study’s 
trajectory can offer valuable information to the research 
and global health community and are most useful when 
published at the time of research activities, not with 
final results. Standardising definitions of variables and 
outcomes, and establishing biorepository standards will 
catalyse the acceleration of discovery science—by facili-
tating the creation of virtual cohorts that bring together 
otherwise disparate studies. Given the time and effort 
required from both researchers and study participants to 
obtain, store and analyse biological data and samples, it is 
crucial that they are used equitably, ethically and to their 
full capacity, even once primary objectives of studies have 
been assessed and completed. To facilitate collaborative 
research, we recommend that SSA pregnancy cohorts are 
registered on one of the international birth cohort regis-
tries, such as  birthcohorts. net, or consider developing an 
SSA- specific registry.
CONCLUSION
An increasing number of pregnancy studies in SSA 
include biorepositories, with maternal, cord blood, and 
placenta samples being those most commonly collected 
and stored. Future research will be most beneficial and 
impactful if it is complementary to these existing biobanks. 
In addition, studies focusing on maternal–infant dyads 
with a view to understanding the life course of health and 
disease, and in under- represented geographic regions, 
have the potential to make meaningful contributions 
to understanding the early life origins of disease. These 
activities, taken together, should lend strength to global 
health partnerships and alliances.
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